Antares Pharma (NASDAQ:ATRS) announced 4Q2013 and FY2013 results before the market open on March 13, and investors weren't impressed. The company reported 4Q2013 loss of $0.04 per share on revenue of $4.7m, which was pretty much in-line with my expectations, but the stock ended up closing down over 5.6% on twice the average daily volume. I don't think the drop in the stock price should be attributed to the actual results, however, but instead on the continued slow development of the Teva (NYSE:TEVA) programs and lack of details provided on the conference call. Although we may not have seen capitulation yet as retail investors throw in the towel, I do think we are nearing a bottom...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|